Esperion Home | Esperion Therapeutics, Inc.
Esperion is dedicated to discovering, developing and commercializing innovative and combination medicines to reduce cardiovascular risk.
Investors and Media | Esperion Therapeutics, Inc.
Jan 2, 2025 · The Investor Relations website contains information about Esperion Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts.
Newsroom | Esperion Therapeutics, Inc.
The Investor Relations website contains information about Esperion Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts.
Careers - Esperion Therapeutics, Inc.
If you are interested in joining the Esperion's dynamic team of innovative colleagues who are passionately committed to making a difference in patients’ lives, please see the opportunities …
Pipeline - Esperion Therapeutics, Inc.
The Esperion next-generation ACLY inhibitor discovery program is a world-class approach
Products - Esperion Therapeutics, Inc.
Please see full U.S. Prescribing Information for NEXLIZET. U.S. healthcare professionals, for more information, please visit nexlizethcp.com.. U.S. patients, for more information, please …
Esperion Announces FDA Approval of the NEXLIZET™ (bempedoic …
Feb 26, 2020 · To ensure access, both NEXLETOL and NEXLIZET will be priced at parity. Additionally, Esperion is committed to achieving the lowest branded tier coverage for Medicare …
Esperion Launches New Scientific Website
Feb 24, 2023 · This website, geared towards the scientific and medical communities, delivers information about Esperion’s CLEAR program and the clinical trials comprising the CLEAR …
Events - Esperion Therapeutics, Inc.
Nov 7, 2024 · The Investor Relations website contains information about Esperion Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts.
Stock Information & Analyst Coverage | Esperion Therapeutics, Inc.
The Investor Relations website contains information about Esperion Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts.